CIK 0001761612 · Non-accelerated filer<br>Smaller reporting company
BICYCLE THERAPEUTICS PLC
Sign in to watch- Ticker
- BCYC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- operating
- Phone
- 011441223261503
- Business address
- BLOCKS A & B, PORTWAY BUILDING, GRANTA PARK, GREAT ABINGTON, CAMBRIDGE, United Kingdom, CB21 6GS
- Former names
- BICYCLE THERAPEUTICS Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $64,039
- in 7 filings, $7K under 10b5-1 plans
Net −$64,039. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Lee Kevin −$27K CHIEF EXECUTIVE OFFICER sold 1% of stake
- Swanton Robert Charles −$12K Director sold 18% of stake
- Skynner Michael −$9K CHIEF SCIENTIFIC OFFICER sold 2% of stake
- Perry Jennifer Scott −$7K Chief Operating Officer sold 2% of stake
- Hannay Michael Charles Ferguson −$6K CHIEF PROD & SUPPLY CHAIN OFF sold 2% of stake
Reading 60 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-02 | Thompson Travis Alvin Chief Accounting Officer | Grant or award | +16,000 | 23,979 | ||
| 2024-01-02 | Thompson Travis Alvin Chief Accounting Officer | Grant or award · Employee Stock Option (right to buy) | +31,000 | 31,000 | ||
| 2024-01-02 | Legault Pierre Director | Grant or award | +12,000 | 33,500 | ||
| 2024-01-02 | Legault Pierre Director | Grant or award · Stock Option (right to buy) | +24,000 | 24,000 | ||
| 2024-01-02 | Keen Nicholas Chief Scientific Officer | Grant or award | +28,000 | 66,233 | ||
| 2024-01-02 | Keen Nicholas Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +56,000 | 56,000 | ||
| 2024-01-02 | Bourque Janice Director | Grant or award | +6,000 | 16,750 | ||
| 2024-01-02 | Bourque Janice Director | Grant or award · Stock Option (right to buy) | +12,000 | 12,000 | ||
| 2024-01-02 | Gutierrez-Ramos Jose-Carlos Director | Grant or award | +6,000 | 16,750 | ||
| 2024-01-02 | Gutierrez-Ramos Jose-Carlos Director | Grant or award · Stock Option (right to buy) | +12,000 | 12,000 | ||
| 2024-01-02 | Jordan Veronica GH Director | Grant or award | +6,000 | 16,750 | ||
| 2024-01-02 | Jordan Veronica GH Director | Grant or award · Stock Option (right to buy) | +12,000 | 12,000 | ||
| 2024-01-02 | Winter Gregory Paul Director | Grant or award | +6,000 | 180,677 | ||
| 2024-01-02 | Winter Gregory Paul Director | Grant or award · Stock Option (right to buy) | +12,000 | 12,000 | ||
| 2024-01-02 | Kender Richard N Director | Grant or award | +6,000 | 16,750 | ||
| 2024-01-02 | Kender Richard N Director | Grant or award · Stock Option (right to buy) | +12,000 | 12,000 | ||
| 2024-01-02 | Arroyo Santiago Chief Development Officer | Grant or award | +17,340 | 17,340 | ||
| 2024-01-02 | Arroyo Santiago Chief Development Officer | Grant or award · Employee Stock Option (right to buy) | +35,430 | 35,430 | ||
| 2024-01-02 | Crockett Nigel Chief Business Officer | Grant or award | +22,000 | 51,359 | ||
| 2024-01-02 | Crockett Nigel Chief Business Officer | Grant or award · Employee Stock Option (right to buy) | +44,000 | 44,000 |
Page 13 of 26 · 520 trades